Send to

Choose Destination
See comment in PubMed Commons below
Clin Microbiol Infect. 2010 Dec;16(12):1721-8. doi: 10.1111/j.1469-0691.2010.03365.x. Epub 2010 Nov 5.

Costs of healthcare-associated methicillin-resistant Staphylococcus aureus and its control.

Author information

  • 1Department of Medical Microbiology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK.


Methicillin-resistant Staphylococcus aureus (MRSA) clones have caused a huge worldwide epidemic of hospital-acquired infections over the past 20-30 years and continue to evolve, including the advent of virulent community strains. The burden on healthcare services is highly significant, in particular because MRSA has not replaced susceptible staphylococcal infection but is an additional problem. Treatment strategies for MRSA are suboptimal and compromise the care of patients. MRSA is associated with serious morbidity and mortality, both within and without hospitals. Although the literature on the costs of MRSA and its control is suboptimal, it is clear that the control of MRSA is highly desirable and likely to be cost-effective. Any compromises in control are likely to be false economies.

© 2010 The Authors. Clinical Microbiology and Infection © 2010 European Society of Clinical Microbiology and Infectious Diseases.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk